Cogent Biosciences, Inc.
COGT
$34.29
-$0.24-0.70%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -354.30M | -328.94M | -294.37M | -284.08M | -269.50M |
| Total Depreciation and Amortization | 4.60M | 4.58M | 4.55M | 4.50M | 4.42M |
| Total Amortization of Deferred Charges | 879.00K | 601.00K | 363.00K | -- | -- |
| Total Other Non-Cash Items | 58.11M | 51.30M | 36.80M | 30.58M | 33.18M |
| Change in Net Operating Assets | 5.90M | 8.01M | 6.75M | 15.38M | 10.12M |
| Cash from Operations | -284.82M | -264.44M | -245.92M | -233.61M | -221.77M |
| Capital Expenditure | -1.46M | -1.55M | -818.00K | -1.03M | -1.05M |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -503.91M | -397.97M | -14.27M | 201.18M | 107.66M |
| Cash from Investing | -505.36M | -399.53M | -15.09M | 200.15M | 106.61M |
| Total Debt Issued | 272.39M | 272.39M | 49.29M | 49.29M | -- |
| Total Debt Repaid | -54.64M | -54.64M | 0.00 | -2.07M | -- |
| Issuance of Common Stock | 779.76M | 752.20M | 257.58M | 26.30M | 36.94M |
| Repurchase of Common Stock | -48.90M | -48.90M | -11.57M | -11.57M | -11.57M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -42.82M | -42.82M | -5.70M | 10.90M | 0.00 |
| Cash from Financing | 905.80M | 878.23M | 289.59M | 72.85M | 25.36M |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 115.62M | 214.26M | 28.59M | 39.38M | -89.80M |